Selected publication milestones through 9 October 2026. These dates identify source publication years, not priority claims or a comprehensive history.
2000 — Double-blind PET/treatment study relates D2 occupancy to response and adverse effects. PMID 10739409.
2000 — Depletion imaging tests endogenous baseline occupancy differences. PMID 10884434.
2010 — Regional depletion study localizes a stronger associative than limbic signal. PMID 20194823.
2011 — Prospective high-risk PET study tests temporal association with transition. PMID 21768612.
2012 — Small responder/TRS comparison suggests heterogeneity. PMID 23034655.
2021 — Multicentre STRATA challenges a settled dopamine response classifier. PMID 32910150.
2024 — Registered muscarinic trial improves symptoms without resolving dopamine mediation. PMID 38691387.
Associative and limbic striatum are distinct anatomical hypotheses.
Historical challenge registration, expectancy controls and selective mediator evidence need fuller source recovery.
Treatment resistance and symptomatic remission complicate uniform excess.
Muscarinic efficacy does not demonstrate dopamine dispensability; EMERGENT-3 excluded TRS.
Prospective mechanistic stratification needs independent validation rather than retrospective response-group discrimination.
Prospectively register a selective human dopamine/D2 mediator comparison in anatomically and clinically predefined psychosis strata, measure target engagement and acute-effect expectancy/blinding, use blinded symptom trajectories and an orthogonal nondopaminergic comparator, and prospectively test responses without selecting eligibility from observed treatment outcome.